Macleods Pharmaceuticals IPO – Review, Bid, Size, Allotment, Subscription, GMP & RHP
Last Updated Date: May 25, 2022Macleods Pharmaceuticals Limited, which is the seventh-largest entity in the India Indian pharmaceutical segment as of September 30, 2021, according to AIOCD, has filed the preliminary papers for launching an IPO of about Rs. 5,000 crore in the market.
Until now, the company primarily relied on internal fund sources for funding and accelerating its operations. It is all set to go public with the Offer for Sale IPO.
Macleods Pharmaceuticals IPO is entirely an Offer for Sale of about 6,04,82,040 Equity Shares. Through this Macleods Pharmaceuticals IPO Review, we will study the characteristics of this upcoming IPO.
| Face Value | Rs 1 |
| Price Band | Not Disclosed |
| Listing At | BSE, NSE |
| Min. Order Quantity | Not Disclosed |
| Listing Date | Not Disclosed |
| Offer for Sale | Not Disclosed |
| Fresh Issue | Not Disclosed |
| IPO Size | Not Disclosed |
| Tick Size | 1 |
Macleods Pharmaceuticals IPO Overview
Macleods Pharmaceuticals IPO is an Offer for Sale by the Promoters and Promoter Group.
The selling shareholders will receive the proceeds of the issue. Since there is no Fresh Issue, the company will not receive any proceeds.
Macleods Pharmaceuticals is a diversified entity, and it has attained a unique position in the industry. It offers the development, manufacturing, and marketing of a wide range of formulations that heals various medical issues.
Macleods Pharmaceuticals IPO Important Dates
| Events | Date |
| IPO Opening Date | Not Disclosed |
| IPO Closing Date | Not Disclosed |
| Basis of Allotment Finalization | Not Disclosed |
| Refunds Initiation | Not Disclosed |
| Credit of Shares to Demat Account | Not Disclosed |
| Share Listing Date | Not Disclosed |
The company has not determined Macleods Pharmaceuticals IPO Dates till now.
The company has filed the Draft Red Herring Prospectus (DRHP) with the capital market regulator Securities and Exchange Board of India (SEBI). Company will determine the dates after obtaining the SEBI nod.
Macleods Pharmaceuticals IPO Price, Size, Share Offerings
| Face Value | Rs.1 |
| Price Band | Not Disclosed |
| Offer for Sale | Not Disclosed |
| Fresh Issue | Not Disclosed |
| IPO Size | Not Disclosed |
Macleods Pharmaceuticals IPO Size consists of the Offer for Sale. There is no fresh issue in the IPO. The promoters and promoter group will be offloading their shareholdings in the IPO.
The company will determine the Macleods Pharmaceuticals IPO Price and the selling shareholders in consultation with the Book Running Lead Managers. The face value of the Macleods Pharmaceuticals shares is Rs. 1 each.
The shares will be listed on BSE and NSE.
Macleods Pharmaceuticals IPO Grey Market Premium
| Date | GMP (Rs.) | Kostak Rate (Rs.) | Subject to Sauda (Rs.) |
| Not Disclosed | |||
Another essential aspect of any IPO is its GMP. It is an influencing factor that drives the listing price. The trading in the Grey Market is unofficial.
The market is legal in India; here, the traders trade in the shares of the issuer company before its listing on the stock exchange.
Macleods Pharmaceuticals IPO GMP will be available soon after the company receives the approval of SEBI for the DRHP.
Macleods Pharmaceuticals IPO Subscription Status
| Day / Date | QIB | NII | RII | Total Subscription |
| 1st Day – | ||||
| 2nd Day – | ||||
| 3rd Day – | ||||
| Shares Offered or Net Issue |
Macleods Pharmaceuticals IPO Subscription will be reserved for the different categories in the following manner:
Not more than fifty percent of the offer will be reserved for allocation to the Qualified Institutional Buyers (QIBs). Not less than fifteen percent of the issue will be allocated to the Non-Institutional Bidder, and the remaining thirty-five percent will be available for allocation to the Retail Individual Bidders.
The company will open the IPO to invite bids from the public for a specified period.
Macleods Pharmaceuticals IPO Allotment Status
Macleods Pharmaceuticals IPO Allotment will be finalized after the company receives the applications from the investors to subscribe to the shares.
The basis of allotment will be determined by the company according to the demand for the share in the market and the response to the IPO.
Macleods Pharmaceuticals IPO Live Performance
Check out the Macleods Pharmaceuticals IPO Performance from here at any time. Macleods Pharmaceuticals IPO Price will be available with just a single click for the investors.
Subscribe to Macleods Pharmaceuticals IPO – Open Free Demat Account Now!
Macleods Pharmaceuticals – Company Review
Macleods was formed in 1989 as a private limited company, ‘Macleods Pharmaceuticals Private Limited.’ The company was converted from a private limited company to a public limited company in 1997.
The name was changed from ‘Macleods Pharmaceuticals Private Limited’ to ‘Macleods Pharmaceuticals Limited.’
The company is engaged in developing, manufacturing, and marketing an extensive range of formulations that cure and helps across varied major therapeutic segments.
Its areas include cardiovascular, hormone treatment, anti-infectives, dermatology, and anti-diabetic.
Products or Services
Macleods Pharmaceuticals Limited is a Global distributor and Manufacturer of various Pharmaceutical Products.
It has a remarkable presence in antimalarials, antiasthmatics, antituberculosis, antihypertensives, antiretrovirals, antidiabetics, and antibacterials.
The entity has contributed largely to the country’s pharmaceutical industry and has emerged as the seventh-largest company for it.
Macleods has created a competitive presence, especially in North and East India. About more than half of the company’s revenues are drawn from the domestic market, with a wide ambit of operations.
Promoters and Holding
The Promoters of Macleods Pharmaceuticals Limited are:
- Girdharilal Bawri
- Banwarilal Bawri
- Rajendra Agarwal
The management of the company consists of:
- Mihir Shah, in the position of Chairman and Independent Director
- Girdharilal Bawri, in the position of Founder Executive Director
- Banwarilal Bawri, in the position of Founder Joint Managing Director
- Rajendra Agarwal, in the position of Founder Managing Director
- Arvind Sadashiv Mokashi, in the position of Independent Director
- Vinita Mayur Danait, in the position of Independent Director
- Vijay Agarwal, in the position of Chief Executive Officer
- Patri Venkat Raghavendra Rao, in the position of Chief Financial Officer (Executive Vice President)
- Siddhesh Mahadeo Rane, in the position of Company Secretary
Is Macleods Pharmaceuticals good for Investment?
Macleods Pharmaceuticals Limited has been in operation for over three decades. The entity is in the business of developing, manufacturing, and marketing various pharmaceutical products.
The entity offers solutions for numerous medical challenges and is driven to provide healing for the world and to help people live better.
It has created a special place in the segment of anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment.
Macleods Pharmaceuticals IPO is being proposed to carry out the sale of equity shares by the promoter and promoter group. It will help increase the visibility of the company in the Indian Market.
Macleods Pharmaceuticals Financial Statements
| Amount (in INR & Million) | ||||
| 30-Sept-21 | Mar-21 | 31-Mar-20 | 31-Mar-19 | |
| Assets | 66,158.63 | 57,347.37 | 95,733.87 | 75,688.69 |
| Revenue | 40,937.01 | 77,494.84 | 72,621.33 | 63,128.98 |
| Expense | 33,932.55 | 52,434.58 | 54,023.35 | 47,950.17 |
| Profit After Tax | 6,380.51 | 20,228.44 | 15,721.15 | 14,234.57 |
Macleods Pharmaceuticals Limited is a profit-making company and has secured impressive revenues over the years.
The company’s total income for the years 2019, 2020, and 2021 were – 63,128.98 million, 72,621.33 million, and 77,494.84 million, respectively.
The company’s profits for the years 2019, 2020, and 2021 were – 15,178.81 million, 18,597.98 million, and 25,060.26 million, respectively.
In the half-year of 2021 ended September 30, 2021, the company’s total income was 40,937.01 million, and the profit for the same period was 7,004.46 million.
| Earnings per Equity Share (in Million) | ||||
| 30-Sept-21 | Mar-21 | 31-Mar-20 | 31-Mar-19 | |
| Basic & Diluted | 10.56 | 33.74 | 26.18 | 23.72 |
The EPS of Macleods Pharmaceuticals over the years has been growing. For the financial year 2020-21, the EPS was Rs. 33.74. In the six months of 2021, the company’s EPS was Rs. 10.56.
Macleods Pharmaceuticals IPO Review
Macleods Pharmaceuticals IPO consists of an Offer for Sale of 6,04,82,040 Equity Shares. The IPO does not consist of any Fresh Issue, implying the company will not be issuing any new shares to the applicants.
The promoters, Girdharilal Bawri, Banwarilal Bawri, and Dr. Rajendra Agarwal, will be offering their shares along with Promoter Group, including Prateek Agarwal, Ajay Agarwal, Vijay Agarwal, Anju Agarwal, Gauri Agarwal, Dr. Ruchi Agarwal, and Sudha Bawri.
The IPO is being launched to execute the sale of equity shares and attain the benefits of listing on the stock exchanges. The company’s presence in the market will be enhanced with the upcoming IPO.
Macleods Pharmaceuticals IPO Details
Here are few more details you need to know before investing in Macleods Pharmaceuticals IPO –
Macleods Pharmaceuticals IPO Issue Object
- Monitoring Utilization of Funds
- Other confirmations
Macleods Pharmaceuticals IPO – Basis of Offer Price
The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.
Qualitative factors are:
- Leading and fast-growing company with significant presence in the IPM;
- Proven track record of building brands;
- Diversified presence across global markets with calibrated business model;
- Environmental, social and governance focused, including extensive involvement in global access;
- R&D-led differentiated portfolio of products;
- Diversified and quality-compliant manufacturing capabilities;
- Experienced, professional and stable management team; and
- Strong financial track record.
Quantitative factors are:
| Basic EPS | RONW (%) | NAV (Rs.) | |
| 31-Mar-21 | 33.74 | 53.31 | 63.37 |
| 31-Mar-20 | 26.18 | 20.78 | – |
| Mar-19 | 23.72 | 23.67 | – |
Macleods Pharmaceuticals IPO Lead Managers
Here are the list of Lead managers –
- Kotak Mahindra Capital Company Limited
- Citigroup Global Markets India Private Limited
- Edelweiss Financial Services Limited
- ICICI Securities Limited
- Nomura Financial Advisory and Securities (India) Private Limited
Macleods Pharmaceuticals IPO Registrar to offer
Check out the details of the registrar here –
Kfin Technologies Private Limited
(formerly known as Karvy Fintech Private Limited)
Selenium, Tower B, Plot No. – 31 and
32 Financial District
Nanakramguda, Serilingampally
Hyderabad, Rangareddy 500 032 Telangana, India
Tel: +91 40 6716 2222
E-mail: mpl.ipo@kfintech.com
Website: www.kfintech.com
Investor Grievance ID: einward.ris@kfintech.com
Contact Person: M Murali Krishna
SEBI Registration Number: INR000000221
Macleods Pharmaceuticals IPO – Other Details
- Statutory Auditor – B.A.K.D. & Co and Walker Chandiok & Co LLP
- Legal Counsel to the Company – Cyril Amarchand Mangaldas
- Bankers to the Company – Axis Bank Limited, HDFC Bank Limited, ICICI Bank Limited, State Bank of India
Macleods Pharmaceuticals IPO – Conclusion
Macleods Pharmaceuticals Limited is a competitive entity and among the industry’s top entities. The company caters to numerous requirements of the public. Its constant research and development are one of its strengths.
Macleods Pharmaceuticals IPO is being proposed to offload the shares by the company’s promoters. No new shares will be issued in the IPO. The selling shareholders will receive the proceeds of the IPO.
The company has an impressive outlook on the financial front. Its total income and profits are engrossing every year. The current situation and the continuous developments of the company ensure vast growth opportunities.
Investors can consider investing in the IPO; the pharmaceutical segment is growing and bringing practical innovations for ease of life.
To Subscribe to Macleods Pharmaceuticals IPO – Open Demat Account Now!
Macleods Pharmaceuticals IPO Review FAQs
Check out the FAQs on Macleods Pharmaceuticals IPO –
What is the Issue Size of Macleods Pharmaceuticals IPO?
The Company is making an initial public offer of NA equity shares. They vividly portray the aspects of the issue in this article.
You can check the stats on the fresh issue, Offer for sale, and net issue.
What is the Price band of Macleods Pharmaceuticals IPO?
The price band for this particular IPO ranges between NA. As far as the face value of the share is of concern, it is Rs.1 per share.
What is the Macleods Pharmaceuticals IPO Open Date?
The opening and closing dates for this IPO have been updated. The IPO is set to open on NA, while the closing date is set at NA.
What is the Macleods Pharmaceuticals IPO Allotment Date?
They also have the news regarding the respective allotment dates of this IPO.
Basis of Allotment finalization is on NA, refund initiation is on NA, credit of shares is on NA, and share listing date is on NA.
What is the Macleods Pharmaceuticals IPO Listing Date?
Shares of this company shall be listed in the exchanges NA. The date, when the listing would be done, is stagnant on NA.
Who is the Registrar of Macleods Pharmaceuticals IPO?
One of the reputed registrars is managing the issue of this IPO, i.e. Kfin Technologies Private Limited. Their website will help you regarding the further information you are on the lookout for.
Who is the Promoter of Macleods Pharmaceuticals IPO?
Here are the promoters of this IPO – GIRDHARILAL BAWRI, BANWARILAL BAWRI AND DR. RAJENDRA AGARWAL. You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.
What is the GMP of Macleods Pharmaceuticals IPO?
They have obtained the GMP of this IPO and it is NA. Further insights of Kostak rate and subject to sauda or SS are as well included in this report.
Is Macleods Pharmaceuticals IPO good for Investment?
They have further provided the financial status of the company in this article, from the past few years.
You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.
What is the PAT of Macleods Pharmaceuticals Company?
We have the information of company financials, and according to that, we have the figures from the last few years to provide.
PAT for the financial year 2021 in Million is 20,228.44, 2020 is 15,721.15, 2019 is 14,234.57. PAT from Sept 2021 is 6,380.5.
Featured Topics